tradingkey.logo

908 Devices Q4 revenue beats on FTIR product strength

ReutersMar 3, 2026 12:08 PM


Overview

  • Chemical analysis toolmaker's Q4 revenue rose 21%, beating analyst expectations

  • Net income for Q4 beat analyst expectations

  • Company achieved positive adjusted EBITDA in Q4


Outlook

  • 908 Devices expects 2026 revenue between $64.5 mln and $67.5 mln, up 15%-20% from 2025


Result Drivers

  • FTIR PRODUCT REVENUE - Q4 revenue growth largely driven by increase in FTIR product sales

  • INSTALLED BASE EXPANSION - Installed base grew 24% year-over-year, supporting revenue growth

  • RECURRING REVENUE - Recurring revenue represented 32% of total revenues in the quarter, indicating strong customer retention


Company press release: ID:nBw1sXhpla


Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

Q4 Revenue

Beat

$17.40 mln

$15.84 mln (4 Analysts)

Q4 Net Income

Beat

$4.20 mln

-$3.62 mln (3 Analysts)

Q4 Gross Profit

$9.20 mln

Q4 Operating Expenses

$6.10 mln


Analyst Coverage

  • The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 4 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

  • The average consensus recommendation for the advanced medical equipment & technology peer group is "buy."

  • Wall Street's median 12-month price target for 908 Devices Inc is $10.00, about 51.3% above its March 2 closing price of $6.61


For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI